http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101233154-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
| filingDate | 2006-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101233154-B |
| titleOfInvention | Suppress the stable of TNF α and soluble antibodies |
| abstract | The present invention is particularly to the stable of TNF alpha specific and solvable scFv antibody and Fab fragment, it comprises specificity light chain and sequence of heavy chain, these sequences for the associativity of stability, solubility, in vitro and in vivo and TNF α and reduced immunogenicity optimised.Described antibody is designed to the disorder diagnosed and/or treatment is relevant to TNF α.Also disclose nucleic acid, carrier and the host cell of expressing recombinant antibodies of the present invention, be separated their method and the application of described antibody in medicine. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105153306-A |
| priorityDate | 2005-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 584.